| 1 |
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J]. Lancet, 2018, 390(10114):2769-2778.
|
| 2 |
Biancone L, Annese V, Ardizzone S, et al. Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)[J]. Dig Liver Dis, 2017, 49(4):338-358.
|
| 3 |
Roda G, Jharap B, Neeraj N, et al. Loss of response to Anti-TNFs: definition, epidemiology, and management[J]. Clin Transl Gastroenterol, 2016, 7(1): e135.
|
| 4 |
Papamichael K, Lin S, Moore M, et al. Infliximab in inflammatory bowel disease[J]. Ther Adv Chronic Dis, 2019, 10:2040622319838443.
|
| 5 |
Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse[J]. Inflamm Bowel Dis, 2015, 21(1):182-197.
|
| 6 |
Sala E, Genua M, Petti L, et al. Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine[J]. Gastroenterology, 2015, 149(1): 163-176.
|
| 7 |
Song WJ, Li Q, Ryu MO, et al. TSG-6 released from intraperitoneally injected canine adipose tissue-derived mesenchymal stem cells ameliorate inflammatory bowel disease by inducing M2 macrophage switch in mice[J]. Stem Cell Res Ther, 2018, 9(1):91.
|
| 8 |
Abbaszadeh H, Ghorbani F, Derakhshani M, et al. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles: A novel therapeutic paradigm[J]. J Cell Physiol, 2020, 235(2):706-717.
|
| 9 |
Trams EG, Lauter CJ, Salem N Jr, et al. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles[J]. Biochim Biophys Acta, 1981, 645(1):63-70.
|
| 10 |
Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367(6478): eaau6977.
|
| 11 |
Joo HS, Suh JH, Lee HJ, et al. Current knowledge and future perspectives on mesenchymal stem cell-derived exosomes as a new therapeutic agent[J]. Int J Mol Sci, 2020, 21(3): 727.
|
| 12 |
Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis[J]. J Mol Med (Berl), 2013, 91(4): 431-437.
|
| 13 |
Van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles[J]. Nat Rev Mol Cell Biol, 2018, 19(4):213-228.
|
| 14 |
Yaghoubi Y, Movassaghpour A, Zamani M, et al. Human umbilical cord mesenchymal stem cells derived-exosomes in diseases treatment[J]. Life Sci, 2019, 233:116733.
|
| 15 |
Pegtel DM, Gould SJ. Exosomes[J]. Annu Rev Biochem, 2019, 88:487-514.
|
| 16 |
Trajkovic K, Hsu C, Chiantia S, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes[J]. Science, 2008, 319(5867):1244-1247.
|
| 17 |
Andrzejewska A, Lukomska B, Janowski M. Concise review: Mesenchymal stem cells: from roots to boost[J]. Stem Cells, 2019, 37(7):855-864.
|
| 18 |
Heidari M, Pouya S, Baghaei K, et al. The immunomodulatory effects of adipose-derived mesenchymal stem cells and mesenchymal stem cells-conditioned medium in chronic colitis[J]. J Cell Physiol, 2018, 233(11):8754-8766.
|
| 19 |
Yang J, Liu XX, Fan H, et al. Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation, oxidative stress and apoptosis[J]. PLoS One, 2015, 10(10):e0140551.
|
| 20 |
de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(12):739-749.
|
| 21 |
Cao L, Xu H, Wang G, et al. Extracellular vesicles derived from bone marrow mesenchymal stem cells attenuate dextran sodium sulfate-induced ulcerative colitis by promoting M2 macrophage polarization[J]. Int Immunopharmacol, 2019, 72: 264-274.
|
| 22 |
Mao F, Wu Y, Tang X, et al. Exosomes derived from human umbilical cord mesenchymal stem cells relieve inflammatory bowel disease in mice[J]. Biomed Res Int, 2017, 2017:5356760.
|
| 23 |
Liu H, Liang Z, Wang F, et al. Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism[J]. JCI Insight, 2019, 4(24):e131273.
|
| 24 |
An JH, Li Q, Ryu MO, et al. TSG-6 in extracellular vesicles from canine mesenchymal stem/stromal is a major factor in relieving DSS-induced colitis[J]. PLoS One, 2020, 15(2):e0220756.
|
| 25 |
Iboshi Y, Nakamura K, Fukaura K, et al. Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis[J]. J Gastroenterol, 2017, 52(3):315-326.
|
| 26 |
Chen Q, Duan X, Xu M, et al. BMSC-EVs regulate Th17 cell differentiation in UC via H3K27me3[J]. Mol Immunol, 2020, 118:191-200.
|
| 27 |
An JH, Li Q, Bhang DH, et al. TNF-α and INF-γ primed canine stem cell-derived extracellular vesicles alleviate experimental murine colitis[J]. Sci Rep, 2020, 10(1):2115.
|
| 28 |
Madrigal M, Rao KS, Riordan NH. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods[J]. J Transl Med, 2014, 12:260.
|
| 29 |
Han YD, Bai Y, Yan XL, et al. Co-transplantation of exosomes derived from hypoxia-preconditioned adipose mesenchymal stem cells promotes neovascularization and graft survival in fat grafting[J]. Biochem Biophys Res Commun, 2018, 497(1):305-312.
|
| 30 |
Riazifar M, Mohammadi MR, Pone EJ, et al. Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders[J]. ACS Nano, 2019, 13(6):6670-6688.
|
| 31 |
Holmberg FEO, Pedersen J, Jørgensen P, et al. Intestinal barrier integrity and inflammatory bowel disease: Stem cell-based approaches to regenerate the barrier[J]. J Tissue Eng Regen Med, 2018, 12(4):923-935.
|
| 32 |
Rager TM, Olson JK, Zhou Y, et al. Exosomes secreted from bone marrow-derived mesenchymal stem cells protect the intestines from experimental necrotizing enterocolitis[J]. J Pediatr Surg, 2016, 51(6):942-947.
|
| 33 |
McCulloh CJ, Olson JK, Wang Y, et al. Treatment of experimental necrotizing enterocolitis with stem cell-derived exosomes[J]. J Pediatr Surg, 2018, 53(6):1215-1220.
|
| 34 |
Wu H, Fan H, Shou Z, et al. Extracellular vesicles containing miR-146a attenuate experimental colitis by targeting TRAF6 and IRAK1[J]. Int Immunopharmacol, 2019, 68:204-212.
|
| 35 |
Yang J, Zhou CZ, Zhu R, et al. miR-200b-containing microvesicles attenuate experimental colitis associated intestinal fibrosis by inhibiting epithelial-mesenchymal transition[J]. J Gastroenterol Hepatol, 2017, 32(12): 1966-1974.
|
| 36 |
Wu Y, Qiu W, Xu X, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease in mice through ubiquitination[J]. Am J Transl Res, 2018, 10(7):2026-2036.
|
| 37 |
Harrell CR, Fellabaum C, Jovicic N, et al. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome[J]. Cells, 2019, 8(5):467.
|
| 38 |
Ma ZJ, Wang YH, Li ZG, et al. Immunosuppressive effect of exosomes from mesenchymal stromal cells in defined medium on experimental colitis[J]. Int J Stem Cells, 2019, 12(3):440-448.
|
| 39 |
Matei AC, Antounians L, Zani A. Extracellular vesicles as a potential therapy for neonatal conditions: state of the art and challenges in clinical translation[J]. Pharmaceutics, 2019, 11(8):404.
|
| 40 |
Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines[J]. J Extracell Vesicles, 2018, 7(1):1535750.
|
| 41 |
Konoshenko MY, Lekchnov EA, Vlassov AV, et al. Isolation of extracellular vesicles: general methodologies and latest trends[J]. Biomed Res Int, 2018, 2018:8545347.
|